Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.

Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG.

Clin Gastroenterol Hepatol. 2019 Sep 20. pii: S1542-3565(19)31027-4. doi: 10.1016/j.cgh.2019.09.021. [Epub ahead of print]

PMID:
31546056
2.

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.

Koelink PJ, Bloemendaal FM, Li B, Westera L, Vogels EWM, van Roest M, Gloudemans AK, van 't Wout AB, Korf H, Vermeire S, Te Velde AA, Ponsioen CY, D'Haens GR, Verbeek JS, Geiger TL, Wildenberg ME, van den Brink GR.

Gut. 2019 Sep 10. pii: gutjnl-2019-318264. doi: 10.1136/gutjnl-2019-318264. [Epub ahead of print]

3.

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.

Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR.

Gastroenterology. 2019 Sep 4. pii: S0016-5085(19)41300-0. doi: 10.1053/j.gastro.2019.08.043. [Epub ahead of print]

4.

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.

Berends SE, van Steeg TJ, Ahsman MJ, Singh S, Brandse JF, D'Haens GRAM, Mathôt RAA.

J Pharmacokinet Pharmacodyn. 2019 Sep 5. doi: 10.1007/s10928-019-09652-5. [Epub ahead of print]

PMID:
31489538
5.

Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease.

Ma C, Gecse KB, Duijvestein M, Sandborn WJ, Zou G, Shackleton LM, Stitt LW, Parker CE, Bossuyt P, Löwenberg M, Khanna R, Vermeire S, Rutgeerts P, Feagan BG, Jairath V, D'Haens GR.

Clin Gastroenterol Hepatol. 2019 Aug 29. pii: S1542-3565(19)30921-8. doi: 10.1016/j.cgh.2019.08.046. [Epub ahead of print]

PMID:
31473359
6.

Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease using Dried Blood Samples.

Berends SE, Bloem K, de Vries A, Schaap T, Rispens T, Strik AS, Talwar R, Löwenberg M, D'Haens GR, Mathôt RA.

Ther Drug Monit. 2019 Aug 26. doi: 10.1097/FTD.0000000000000686. [Epub ahead of print]

PMID:
31464823
7.

Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data from 5 Randomized Controlled Induction Trials.

Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D'Haens GR, Jairath V.

Clin Gastroenterol Hepatol. 2019 Aug 20. pii: S1542-3565(19)30900-0. doi: 10.1016/j.cgh.2019.08.025. [Epub ahead of print]

PMID:
31442599
8.

Prospective cohort study of appendicectomy for treatment of therapy-refractory ulcerative colitis.

Stellingwerf ME, Sahami S, Winter DC, Martin ST, D'Haens GR, Cullen G, Doherty GA, Mulcahy H, Bemelman WA, Buskens CJ.

Br J Surg. 2019 Aug 8. doi: 10.1002/bjs.11259. [Epub ahead of print]

PMID:
31393608
9.

IBD-Associated Dysplastic Lesions Show More Chromosomal Instability Than Sporadic Adenomas.

Wanders LK, Cordes M, Voorham Q, Sie D, de Vries SD, d'haens GRAM, de Boer NKH, Ylstra B, van Grieken NCT, Meijer GA, Dekker E, Carvalho B.

Inflamm Bowel Dis. 2019 Aug 2. pii: izz171. doi: 10.1093/ibd/izz171. [Epub ahead of print]

PMID:
31372648
10.

Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.

van Gennep S, Konté K, Meijer B, Heymans MW, D'Haens GR, Löwenberg M, de Boer NKH.

Aliment Pharmacol Ther. 2019 Sep;50(5):484-506. doi: 10.1111/apt.15403. Epub 2019 Jul 25. Review.

PMID:
31342537
11.

Diagnostic Accuracy of Transabdominal Ultrasound in detecting intestinal inflammation in paediatric IBD patients- a systematic review.

van Wassenaer EA, de Voogd FAE, van Rijn RR, van der Lee JH, Tabbers MM, van Etten-Jamaludin FS, Gecse KB, Kindermann A, de Meij TGJ, D'Haens GR, Benninga MA, Koot BGP.

J Crohns Colitis. 2019 Apr 23. pii: jjz085. doi: 10.1093/ecco-jcc/jjz085. [Epub ahead of print]

PMID:
31329839
12.

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.

Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR.

Gut. 2019 Jul 8. pii: gutjnl-2019-318256. doi: 10.1136/gutjnl-2019-318256. [Epub ahead of print]

13.

Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.

de Groof EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, Bosmans JE, van Dongen JM, Mol B, Buskens CJ, Stokkers PCF, Hart A, D'Haens GR, Bemelman WA, Ponsioen CY; LIR!C study group.

Gut. 2019 Oct;68(10):1774-1780. doi: 10.1136/gutjnl-2018-317539. Epub 2019 Feb 1.

PMID:
31233395
14.

Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection.

D'Haens GR, Jobin C.

Gastroenterology. 2019 Sep;157(3):624-636. doi: 10.1053/j.gastro.2019.04.053. Epub 2019 Jun 17. Review.

PMID:
31220424
15.

Hyperbaric oxygen therapy for the treatment of perianal fistulas in Crohn's disease (HOT-TOPIC): study protocol of a prospective interventional cohort study with one-year follow-up.

Lansdorp CA, Gecse KB, Buskens CJ, Land Wenberg M, Stoker J, Bemelman WA, D'Haens GRAM, van Hulst RA.

Undersea Hyperb Med. 2019 Jan-Feb;46(1):45-53.

PMID:
31154684
16.

Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.

Berends SE, Strik AS, Jansen JM, de Boer NK, van Egmond PS, Brandse JF, Mathôt RA, D'Haens GR, Löwenberg M.

Scand J Gastroenterol. 2019 Jun;54(6):700-706. doi: 10.1080/00365521.2019.1619828. Epub 2019 May 27.

PMID:
31132014
17.

Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas.

Stevens TW, D'Haens GR, Duijvestein M, Bemelman WA, Buskens CJ, Gecse KB.

United European Gastroenterol J. 2019 May;7(4):496-506. doi: 10.1177/2050640619834464. Epub 2019 Feb 24.

18.

Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.

Strik AS, Löwenberg M, Buskens CJ, B Gecse K, I Ponsioen C, Bemelman WA, D'Haens GR.

Scand J Gastroenterol. 2019 Apr;54(4):453-458. doi: 10.1080/00365521.2019.1600014. Epub 2019 Apr 28.

PMID:
31032686
19.

Infliximab biosimilar CT-P13 in Crohn's disease.

Gecse KB, D'Haens GR.

Lancet. 2019 Apr 27;393(10182):1671-1672. doi: 10.1016/S0140-6736(18)32778-8. Epub 2019 Mar 28. No abstract available.

PMID:
30929894
20.

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.

Berends SE, D'Haens GRAM, Schaap T, de Vries A, Rispens T, Bloem K, Mathôt RAA.

Br J Clin Pharmacol. 2019 Jul;85(7):1544-1551. doi: 10.1111/bcp.13939. Epub 2019 May 11.

21.

Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.

Bots SJ, Kuin S, Ponsioen CY, Gecse KB, Duijvestein M, D'Haens GR, Löwenberg M.

Scand J Gastroenterol. 2019 Mar;54(3):281-288. doi: 10.1080/00365521.2019.1582693. Epub 2019 Mar 23.

PMID:
30907185
22.

Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease.

van Aalst M, Garcia Garrido HM, van der Leun J, Meek B, van Leeuwen EMM, Löwenberg M, D'Haens GR, Ponsioen CYI, Grobusch MP, Goorhuis A.

Clin Infect Dis. 2019 Mar 22. pii: ciz226. doi: 10.1093/cid/ciz226. [Epub ahead of print]

PMID:
30899961
23.

Ulcerative Colitis: Shifting Sands.

D'Haens GRAM, Lindsay JO, Panaccione R, Schreiber S.

Drugs R D. 2019 Jun;19(2):227-234. doi: 10.1007/s40268-019-0263-2.

24.

Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD.

Duijvestein M, D'Haens GR.

Expert Opin Biol Ther. 2019 Apr;19(4):361-366. doi: 10.1080/14712598.2019.1576631. Epub 2019 Feb 11.

PMID:
30696342
25.

A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function.

De Vries LCS, Duarte JM, De Krijger M, Welting O, Van Hamersveld PHP, Van Leeuwen-Hilbers FWM, Moerland PD, Jongejan A, D'Haens GR, De Jonge WJ, Wildenberg ME.

Inflamm Bowel Dis. 2019 Mar 14;25(4):647-660. doi: 10.1093/ibd/izy364.

PMID:
30668755
26.

Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.

Panés J, D'Haens GR, Higgins PDR, Mele L, Moscariello M, Chan G, Wang W, Niezychowski W, Su C, Maller E.

Aliment Pharmacol Ther. 2019 Feb;49(3):265-276. doi: 10.1111/apt.15072.

27.

Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort Study.

Samaan MA, Forsyth K, Segal JP, De Jong D, Vleugels JLA, Elkady S, Kabir M, Campbell S, Kok K, Armstrong DG, Penez L, Arenaza AP, Seward E, Vega R, Mehta S, Rahman F, McCartney S, Bloom S, Patel K, Pollok R, Westcott E, Darakhshan A, Williams A, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Dekker E, D'Haens GR, Hart A, Irving PM.

J Crohns Colitis. 2019 May 27;13(6):735-743. doi: 10.1093/ecco-jcc/jjy225.

PMID:
30590513
28.

A distinct epigenetic profile distinguishes stenotic from non-inflamed fibroblasts in the ileal mucosa of Crohn's disease patients.

Li Yim AYF, de Bruyn JR, Duijvis NW, Sharp C, Ferrero E, de Jonge WJ, Wildenberg ME, Mannens MMAM, Buskens CJ, D'Haens GR, Henneman P, Te Velde AA.

PLoS One. 2018 Dec 27;13(12):e0209656. doi: 10.1371/journal.pone.0209656. eCollection 2018.

29.

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.

Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035. Epub 2018 Nov 23.

30.

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy.

Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D'Haens GR.

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1213-1231. doi: 10.1111/apt.15033. Epub 2018 Oct 30.

PMID:
30378142
31.

Definitions of response and remission for the Robarts Histopathology Index.

Pai RK, Khanna R, D'Haens GR, Sandborn WJ, Jeyarajah J, Feagan BG, Vande Casteele N, Jairath V.

Gut. 2019 Nov;68(11):2101-2102. doi: 10.1136/gutjnl-2018-317547. Epub 2018 Oct 26. No abstract available.

PMID:
30366909
32.

A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score.

Jairath V, Jeyarajah J, Zou G, Parker CE, Olson A, Khanna R, D'Haens GR, Sandborn WJ, Feagan BG.

Lancet Gastroenterol Hepatol. 2019 Jan;4(1):63-70. doi: 10.1016/S2468-1253(18)30306-6. Epub 2018 Oct 18.

PMID:
30343116
33.

The Risk of Colectomy and Colorectal Cancer After Appendectomy in Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis.

Stellingwerf ME, de Koning MA, Pinkney T, Bemelman WA, D'Haens GR, Buskens CJ.

J Crohns Colitis. 2019 Mar 26;13(3):309-318. doi: 10.1093/ecco-jcc/jjy163.

PMID:
30335149
34.

Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity.

de Jong DC, Löwenberg M, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Gecse K, Ponsioen CY, D'Haens GR, Irving PM, Samaan MA.

Inflamm Bowel Dis. 2019 Apr 11;25(5):937-944. doi: 10.1093/ibd/izy325.

PMID:
30329045
35.

Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation: Short-Term Results of the PASSION Study.

Sahami S, Wildenberg ME, Koens L, Doherty G, Martin S, D'Haens GRAM, Cullen G, Bemelman WA, Winter D, Buskens CJ.

J Crohns Colitis. 2019 Feb 1;13(2):165-171. doi: 10.1093/ecco-jcc/jjy127.

PMID:
30285094
36.

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.

Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1525-1532.e1. doi: 10.1016/j.cgh.2018.09.033. Epub 2018 Sep 26.

37.

Persistent Mesorectal Inflammatory Activity is Associated With Complications After Proctectomy in Crohn's Disease.

de Groof EJ, van der Meer JHM, Tanis PJ, de Bruyn JR, van Ruler O, D'Haens GRAM, van den Brink GR, Bemelman WA, Wildenberg ME, Buskens CJ.

J Crohns Colitis. 2019 Mar 26;13(3):285-293. doi: 10.1093/ecco-jcc/jjy131.

PMID:
30203027
38.

Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.

Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK.

Gut. 2019 Jul;68(7):1162-1168. doi: 10.1136/gutjnl-2018-316702. Epub 2018 Aug 3.

PMID:
30076171
39.

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO.

Lancet Gastroenterol Hepatol. 2018 Oct;3(10):671-680. doi: 10.1016/S2468-1253(18)30233-4. Epub 2018 Jul 25.

40.

TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism.

Bloemendaal FM, Koelink PJ, van Schie KA, Rispens T, Peters CP, Buskens CJ, van der Bilt JD, Bemelman WA, Korf H, Sabino JG, Ponsioen CY, Te Velde AA, D'Haens GRAM, van den Brink GR, Wildenberg ME.

J Crohns Colitis. 2018 May 30. doi: 10.1093/ecco-jcc/jjy075. [Epub ahead of print]

PMID:
29860435
41.

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis.

Berends SE, Strik AS, Löwenberg M, D'Haens GR, Mathôt RAA.

Clin Pharmacokinet. 2019 Jan;58(1):15-37. doi: 10.1007/s40262-018-0676-z. Review.

42.

Fibrostenotic Phenotype of Myofibroblasts in Crohn's Disease is Dependent on Tissue Stiffness and Reversed by LOX Inhibition.

de Bruyn JR, van den Brink GR, Steenkamer J, Buskens CJ, Bemelman WA, Meisner S, Muncan V, Te Velde AA, D'Haens GR, Wildenberg ME.

J Crohns Colitis. 2018 Jun 28;12(7):849-859. doi: 10.1093/ecco-jcc/jjy036.

PMID:
29672662
43.

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis.

Samaan MA, Shen B, Mosli MH, Zou G, Sandborn WJ, Shackelton LM, Nelson S, Stitt L, Bloom S, Pardi DS, Gionchetti P, Lindsay J, Travis S, Hart A, Silverberg MS, Feagan BG, D'Haens GR, Jairath V.

Gastrointest Endosc. 2018 Aug;88(2):360-369.e2. doi: 10.1016/j.gie.2018.04.2330. Epub 2018 Apr 13.

PMID:
29660321
44.

Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease.

Koelink PJ, Wildenberg ME, Stitt LW, Feagan BG, Koldijk M, van 't Wout AB, Atreya R, Vieth M, Brandse JF, Duijst S, Te Velde AA, D'Haens GRAM, Levesque BG, van den Brink GR.

J Crohns Colitis. 2018 Jun 28;12(7):794-803. doi: 10.1093/ecco-jcc/jjy035.

45.

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.

Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR; SECURE study group.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412. doi: 10.1016/S2468-1253(18)30082-7. Epub 2018 Mar 30.

PMID:
29606564
46.

Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review.

Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V.

Clin Gastroenterol Hepatol. 2018 Sep;16(9):1407-1419.e22. doi: 10.1016/j.cgh.2018.02.051. Epub 2018 Mar 27. Review.

PMID:
29596987
47.

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease.

Berends SE, Strik AS, Van Selm JC, Löwenberg M, Ponsioen CY, DʼHaens GR, Mathôt RA.

Ther Drug Monit. 2018 Apr;40(2):202-211. doi: 10.1097/FTD.0000000000000494.

PMID:
29529008
48.

Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.

Strik AS, D'Haens GR.

Aliment Pharmacol Ther. 2018 Apr;47(7):1041-1042. doi: 10.1111/apt.14570. No abstract available.

49.

Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease.

Duijvestein M, Battat R, Vande Casteele N, D'Haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG.

Curr Treat Options Gastroenterol. 2018 Mar;16(1):129-146. doi: 10.1007/s11938-018-0175-1. Review.

PMID:
29411220
50.

Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.

Hoekman DR, Stibbe JA, Baert FJ, Caenepeel P, Vergauwe P, De Vos M, Hommes DW, Benninga MA, Vermeire SA, D'Haens GR; BIRD (Belgian Inflammatory Bowel Disease Research and Development) Group; North-Holland Gut Club.

J Crohns Colitis. 2018 Apr 27;12(5):517-524. doi: 10.1093/ecco-jcc/jjy014.

PMID:
29401297

Supplemental Content

Loading ...
Support Center